Skip to content

What clinic visits used to keep you from.

COMPARISON

Same science. Without the clinic.

Real immunotherapy — same allergen extracts, same mechanism — without the clinic visits, the wait, or the multi-year time commitment. Allergy shots and Easily are the same idea executed two different ways; this page compares what each asks of your week.

Why patients quit allergy shots

  • Clinic time

    30+ min/week between travel, the injection, and the mandatory observation window.

  • Adherence

    Only 26–38% of patients finish a course in real-world data; most quit before durable benefit.

  • Cost beyond co-pays

    Lost work hours, travel, parking — the line items the EOB doesn't show.

How Easily addresses each

  • In your bathroom

    0 additional minutes — the dose is built into the brushing routine you already keep.

  • 80% adherence in pilot

    12-month adherence in the OMIT arm of a head-to-head pilot of OMIT versus SLIT (Reisacher 2016, n=24, single site).

  • $99/month

    FSA/HSA eligible. 90-day money-back guarantee. No clinic visits to schedule against your week.

Side-by-side.

Two routes to the same immune outcome. The science is the same; the delivery — and what it asks of your week — is not.

easily

Completion of multi-year course (real-world data)
80% adherence in head-to-head pilot (Reisacher 2016, n=24)
Additional daily time required
0 additional minutes (built into brushing)
Where you do it
Your bathroom
Treats the underlying cause
Yes
FDA-listed allergens
Yes
Money-back guarantee
90 days

Allergy shots

Completion of multi-year course (real-world data)
26–38%
Additional daily time required
30+ min/wk clinic visits
Where you do it
Allergist's office
Treats the underlying cause
Yes
FDA-listed allergens
Yes
Money-back guarantee
No

Sources: Reisacher WR, Suurna MV, Rochlin K, Bremberg MG, Tropper G. Allergy & Rhinology (Providence) 2016;7(1):21–28 — single-site head-to-head pilot of OMIT vs SLIT (n=24, 12 months). The OMIT-vs-SLIT difference in adherence was not statistically significant in this pilot (p=0.61). Real-world SCIT completion rates from standard immunotherapy adherence literature.

What it looked like for one shots-quitter

Natural color editorial portrait of Priya R., Seattle.
“As a clinical researcher, I'm naturally skeptical of consumer wellness claims. However, the OMIT delivery system and the IgG4 'blocking antibody' biomarker research are incredibly compelling. After about eight months on the daily ritual, my reactivity to spring tree pollen is dramatically lower. The science behind oral mucosal immunotherapy is well-documented; what I didn't expect was how genuinely seamless integrating it into my brushing routine would be. I no longer just manage my symptoms; I've fundamentally altered my immune response. It's a sophisticated solution delivered through a remarkably simple daily habit.”
Priya R., Clinical Researcher, Seattle